Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
暂无分享,去创建一个
M. Dougados | S. van der Linden | D. M. van der Heijde | R. Landewé | John A. Davis | D. Heijde | J. Braun | J. Sieper | D van der Heijde | M Dougados | S van der Linden | R Landewé | J Braun | J Davis | J Sieper | C Lukas | C. Lukas | D. Heijde | J. Davis | J. Davis | S. V. D. Linden | Juergen Braun | J. Braun
[1] L. Klareskog,et al. Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description , 2004, Annals of the rheumatic diseases.
[2] van der Heijde Dm,et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993 .
[3] D. M. van der Heijde,et al. Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. , 2004, Arthritis and rheumatism.
[4] W. Maksymowych,et al. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy. , 2004, Journal of Rheumatology.
[5] K L Haywood,et al. Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. , 2002, Rheumatology.
[6] Jacob Cohen. Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.
[7] D. M. van der Heijde,et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. , 2008, Arthritis and rheumatism.
[8] M. Dougados,et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. , 1999, The Journal of rheumatology.
[9] P. Tugwell,et al. OMERACT: An international initiative to improve outcome measurement in rheumatology , 2007, Trials.
[10] A. Calin,et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.
[11] S. van der Linden,et al. Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. , 2001, Arthritis and rheumatism.
[12] D. M. van der Heijde,et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. , 2008, Arthritis and rheumatism.
[13] P. Tugwell,et al. The OMERACT filter for Outcome Measures in Rheumatology. , 1998, The Journal of rheumatology.
[14] M. A. van 't Hof,et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993, The Journal of rheumatology.
[15] M. Dougados,et al. Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. , 2005, Rheumatology.
[16] M. Dougados,et al. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis , 2006, Annals of the rheumatic diseases.
[17] P. Lachenbruch. Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .